FindTrial
Sign In

Clinical study of autologous platelet rich plasma collected by COM. TEC machine in the treatment of middle and early stage osteoarthritis

Clinical study of autologous platelet rich plasma collected by COM. TEC machine in the treatment of middle and early stage osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065410
Enrollment
Unknown
Registered
2022-11-04
Start date
2022-11-04
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Control:Sodium hyaluronate injection into knee joint
experimental group:Injection of platelet rich plasma collected from knee joint

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 45-70 years; 2. Primary knee osteoarthritis; 3. Imaging KL grade of affected knee <= 2; 4. Coagulation function: D-dimer quantitative (DD) < 255 ng/mL, plasma prothrombin time (PT) 8.8-13.4 S, prothrombin activity (PTA) 70-160%, thrombin time (TT) 11.0-17.8 S, activated partial thrombin time (APTT) 23.3-38.1 S; 5. IL-6 < 7 pg/ml; 6. Blood routine examination: RBC 3.8-5.8 x 10^12/L, hemoglobin 115-175 g/L, white blood cell 3.5-9.5 x 10^9/L, platelet count 125-350 x 10^9/L, the percentage of neutrophils is 40-75%.

Exclusion criteria

Exclusion criteria: 1. The patients were treated with intrasegmental injection within 3 months; 2. Infection of the knee joint occurred within 12 weeks, or injury of the knee joint occurred within 12 weeks; 3. Rheumatoid arthritis and other inflammatory arthritis; 4. Tumor patients; 5. Patients with large cartilage defects; 6. Patients with gastrointestinal ulcer, coronary heart disease and other contraindications to use NSAIDs; 7. Patients with local skin disease and systemic allergic disease of knee joint; 8. Diabetes patients; 9. Blood system diseases; 10. Patients with immune deficiency and those who have received immunosuppressive therapy within 12 weeks; 11. Have received anticoagulation or anti polymerization treatment within 4 weeks; 12. There are other serious diseases in the body that cannot cooperate with the study.

Design outcomes

Primary

MeasureTime frame
The Western Ontario and McMaster Universities (WOMAC) ranking;—

Secondary

MeasureTime frame
Knee MRI;Visual Analogue Scale (VAS) score;The 12-item short from health survey (SF-12) score;Lysholm score;—

Countries

China

Contacts

Public ContactYao Shunyu

Beijing Hospital

330633615@qq.com+86 18610899250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026